Alcon Inc. (ALC)
Automate Your Wheel Strategy on ALC
With Tiblio's Option Bot, you can configure your own wheel strategy including ALC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALC
- Rev/Share 20.2443
- Book/Share 44.689
- PB 1.7149
- Debt/Equity 0.2375
- CurrentRatio 2.6015
- ROIC 0.0424
- MktCap 37861152000.0
- FreeCF/Share 3.2276
- PFCF 23.688
- PE 35.3424
- Debt/Assets 0.1673
- DivYield 0.0044
- ROE 0.0493
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ALC | JP Morgan | Overweight | Neutral | -- | -- | Aug. 21, 2025 |
| Downgrade | ALC | Deutsche Bank | Buy | Hold | -- | -- | May 20, 2025 |
| Reiterated | ALC | BTIG Research | -- | Buy | $102 | $99 | May 14, 2025 |
| Reiterated | ALC | Needham | -- | Buy | $107 | $110 | March 28, 2025 |
| Upgrade | ALC | BofA Securities | Neutral | Buy | -- | -- | March 25, 2025 |
| Reiterated | ALC | Needham | -- | Buy | $108 | $106 | Jan. 24, 2025 |
| Upgrade | ALC | Redburn Atlantic | Neutral | Buy | -- | -- | Jan. 10, 2025 |
| Reiterated | ALC | Needham | -- | Buy | $103 | $108 | Dec. 17, 2024 |
| Upgrade | ALC | Redburn Atlantic | Sell | Neutral | -- | -- | Oct. 10, 2024 |
| Upgrade | ALC | RBC Capital Mkts | Sector Perform | Outperform | -- | -- | Sept. 10, 2024 |
News
Here's Why Alcon (ALC) is a Strong Momentum Stock
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
Published: October 14, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (“SEC”) of a “supplement” to the Company's definitive proxy statement, filed on September 16, 2025, in connection with the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). Broadwood, which owns 27.5% of STAAR.
Read More
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
Published: October 08, 2025 by: Business Wire
Sentiment: Neutral
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC (“Glass Lewis”) related to STAAR's pending merger with Alcon (SIX/NYSE: ALC): The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis.
Read More
Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
Published: October 07, 2025 by: PRNewsWire
Sentiment: Neutral
CHARLOTTE, N.C. , Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement outlining its opposition of the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE: ALC): We have been significant STAAR shareholders for more than ten years and remain convicted in the significant value of the Company.
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).
Read More
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical's Sale to Alcon
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today announced that it has published a presentation outlining why stockholders should vote on Broadwood's GREEN Proxy Card “AGAINST” the proposed acquisition of the Company by an affiliate of Alcon Inc. (NYSE: ALC) on the terms announced on August 5, 2025. The 81-pa.
Read More
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced,.
Read More
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.
Read More
Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
Read More
STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
Published: September 16, 2025 by: Business Wire
Sentiment: Neutral
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Alcon (SIX/NYSE: ALC). STAAR will hold a Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote to adopt the.
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).
Read More
Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Negative
ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.
Read More
Alcon: More Than Meets The Eye
Published: August 20, 2025 by: Seeking Alpha
Sentiment: Positive
Alcon remains a leader in eye care, benefiting from strong market positioning and long-term industry tailwinds like aging populations and technological advances. Recent M&A activity, including the STAAR Surgical acquisition, enhances long-term growth but pressures near-term earnings and raises valuation concerns. Despite solid sales growth and manageable debt, shares trade at a demanding 29-30x earnings multiple, which I view as fully valued given current growth rates.
Read More
Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).
Read More
Alcon Stock Gains Following UNITY VCS' Approval in Canada
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
Read More
Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
Published: July 08, 2025 by: Business Wire
Sentiment: Neutral
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. “Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who help.
Read More
Is it Apt to Retain Alcon Stock in Your Portfolio for Now?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Negative
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
Read More
Alcon Canada Earns Global Recognition as a Top Employer
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a recognized authority on identifying excellence in people practices and workplace culture. Being certified as a Top Employer showcases Alcon Canada's commitment to building a better world of work through exceptional HR policies and forward-thinking people practices. This recog.
Read More
Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System
Published: June 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years
Read More
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Published: June 20, 2025 by: Business Wire
Sentiment: Neutral
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theore.
Read More
Alcon Stock Rises Following the FDA Approval of TRYPTYR
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
Read More
Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more
Published: May 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses. The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses.
Read More
Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Alcon Inc. (NYSE:ALC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Jack Reynolds-Clark - RBC Capital Markets Graham Doyle - UBS Ryan Zimmerman - BTIG David Saxon - Needham & Company Larry Biegelsen - Wells Fargo Patrick Wood - Morgan Stanley Anthony Petrone - Mizuho Group Tom Stephan - Stifel Brett Fishbin - KeyBanc Capital Markets Young Li - Jefferies Jeff Johnson - Baird David Adlington - JPMorgan …
Read More
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative
ALC ends the first quarter of 2025 on a disappointing note.
Read More
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Alcon (ALC) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Alcon Announces Results of 2025 Annual General Meeting
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2025 Annual General Meeting.
Read More
Alcon Announces Results of 2025 Annual General Meeting
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2025 Annual General Meeting.
Read More
Alcon Publishes Agenda for 2025 Annual General Meeting
Published: April 04, 2025 by: Business Wire
Sentiment: Neutral
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting.
Read More
Alcon Publishes Agenda for 2025 Annual General Meeting
Published: April 04, 2025 by: Business Wire
Sentiment: Neutral
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting.
Read More
About Alcon Inc. (ALC)
- IPO Date 2019-04-09
- Website https://www.alcon.com
- Industry Medical - Instruments & Supplies
- CEO David J. Endicott
- Employees 25599